High expression of MAGE-A9 contributes to stemness and malignancy of human hepatocellular carcinoma

Wei, Youping; Wang, Yanqin; Gong, Jing; Rao, Lihua; Wu, Zhiwei; Nie, Teng; Shi, Dongling; Zhang, Liming

doi:10.3892/ijo.2017.4198

Cited by 17 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MAGE-A9, a member of the MAGE-A gene family, is frequently expressed in various human tumors (Gu et al, 2014). MAGE-A9 contributes to malignant biological phenotypes, including cell proliferation, chemoresistance and migration of EpCAM + HCC cells (Wei et al, 2018).…”

Section: Rack1 Tg737 and Mage-a9mentioning

confidence: 99%

Recent Advances in Liver Cancer Stem Cells: Non-coding RNAs, Oncogenes and Oncoproteins

Zhu

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide, with high morbidity, relapse, metastasis and mortality rates. Although liver surgical resection, transplantation, chemotherapy, radiotherapy and some molecular targeted therapeutics may prolong the survival of HCC patients to a certain degree, the curative effect is still poor, primarily because of tumor recurrence and the drug resistance of HCC cells. Liver cancer stem cells (LCSCs), also known as liver tumor-initiating cells, represent one small subset of cancer cells that are responsible for disease recurrence, drug resistance and death. Therefore, understanding the regulatory mechanism of LCSCs in HCC is of vital importance. Thus, new studies that present gene regulation strategies to control LCSC differentiation and replication are under development. In this review, we provide an update on the latest advances in experimental studies on non-coding RNAs (ncRNAs), oncogenes and oncoproteins. All the articles addressed the crosstalk between different ncRNAs, oncogenes and oncoproteins, as well as their upstream and downstream products targeting LCSCs. In this review, we summarize three pathways, the Wnt/β-catenin signaling pathway, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway, and interleukin 6/Janus kinase 2/signal transducer and activator of transcription 3 (IL6/JAK2/STAT3) signaling pathway, and their targeting gene, c-Myc. Furthermore, we conclude that octamer 4 (OCT4) and Nanog are two important functional genes that play a pivotal role in LCSC regulation and HCC prognosis.

show abstract

Section: Rack1 Tg737 and Mage-a9mentioning

confidence: 99%

Recent Advances in Liver Cancer Stem Cells: Non-coding RNAs, Oncogenes and Oncoproteins

Zhu

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Subsequently, Youping Wei [45] found that high expression of MAGEA9 contributes to stemness and malignancy of HCC.…”

Section: Discussionmentioning

confidence: 99%

A comprehensive analysis of the MAGE family as prognostic and diagnostic markers for hepatocellular carcinoma

Gong

Xiao

et al. 2020

Genomics

View full text Add to dashboard Cite

Background: The Melanoma Antigen Gene (MAGE) family is a large, highly conserved group of proteins that share a common MAGE homology domain. Multiple MAGEs are aberrantly expressed in a variety of cancers. However, the function of distinct MAGE genes in hepatocellular carcinoma (HCC) is largely unclear. Our study aimed to comprehensively analyze the MAGE family as prognostic and diagnostic markers for HCC. Methods: In this research, all HCC data were obtained from NCBI GEO DataSets, The Cancer Genome Atlas (TCGA) and our clinical center. UALCAN was used to reveal the expression pro le of distinct MAGEs in HCC and further evaluate the association between the expression of MAGEs and the clinicopathological characteristics of HCC patients, including clinical stage, tumor grade. Kaplan-Meier Plotter (KM-Plot) was used to evaluate the correlation between MAGEs expression and the overall survival (OS) of HCC patients. qRT-PCR was used to detection the expression levels of MAGEs in HCC samples. cBioPortal was used to analyze the genetic alterations in MAGEs and their associations with OS of HCC patients. Gene Set Variation Analysis (GSVA) algorithm was used to do functional enrichment analysis of MAGE genes in HCC to reveal the molecular mechanisms of MAGEs functioned in HCC. Results: Our research showed that many MAGE genes were dysregulated in HCC and most of them were highly expressed. Among them, MAGEA1 MAGEC2 MAGED1 MAGED2 MAGEF1 and MAGEL2 were signi cantly correlated with clinical stage and differentiation of HCC patients. MAGED1 MAGED2 MAGEA6 MAGEA12 MAGEA10 MAGEB4 MAGEL2 and MAGEC3 had signi cant correlation with HCC prognosis. Further functional enrichment analysis suggested the dysregulated MAGEs may play important roles in signal transduction. Conclusions: Taken together, our research revealed that multiple MAGEs were dysregulated in HCC and they might play important roles in the development of HCC and can be exploited as useful biomarkers for diagnosis and treatment for HCC.

show abstract

“…The results indicated that MAGEA9 expression is a valuable prognostic biomarker for HCC and high MAGEA9 expression suggests unfavorable survival outcomes in HCC patients. Subsequently, Youping Wei [45] found that high expression of MAGEA9 contributes to stemness and malignancy of HCC.…”

Section: Discussionmentioning

confidence: 99%

A Comprehensive Analysis of the MAGE Family as Prognostic and Diagnostic Markers for Hepatocellular Carcinoma

Gong

Xiao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The Melanoma Antigen Gene (MAGE) family is a large, highly conserved group of proteins that share a common MAGE homology domain. Multiple MAGEs are aberrantly expressed in a variety of cancers. However, the function of distinct MAGE genes in hepatocellular carcinoma (HCC) is largely unclear. Our study aimed to comprehensively analyze the MAGE family as prognostic and diagnostic markers for HCC. Methods: In this research, all HCC data were obtained from NCBI GEO DataSets, The Cancer Genome Atlas (TCGA) and our clinical center. UALCAN was used to reveal the expression profile of distinct MAGEs in HCC and further evaluate the association between the expression of MAGEs and the clinicopathological characteristics of HCC patients, including clinical stage, tumor grade. Kaplan-Meier Plotter (KM-Plot) was used to evaluate the correlation between MAGEs expression and the overall survival (OS) of HCC patients. qRT-PCR was used to detection the expression levels of MAGEs in HCC samples. cBioPortal was used to analyze the genetic alterations in MAGEs and their associations with OS of HCC patients. Gene Set Variation Analysis (GSVA) algorithm was used to do functional enrichment analysis of MAGE genes in HCC to reveal the molecular mechanisms of MAGEs functioned in HCC. Results: Our research showed that many MAGE genes were dysregulated in HCC and most of them were highly expressed. Among them, MAGEA1、MAGEC2、MAGED1、MAGED2、MAGEF1 and MAGEL2 were significantly correlated with clinical stage and differentiation of HCC patients. MAGED1、MAGED2、MAGEA6、MAGEA12、MAGEA10、MAGEB4、MAGEL2 and MAGEC3 had significant correlation with HCC prognosis. Further functional enrichment analysis suggested the dysregulated MAGEs may play important roles in signal transduction. Conclusions: Taken together, our research revealed that multiple MAGEs were dysregulated in HCC and they might play important roles in the development of HCC and can be exploited as useful biomarkers for diagnosis and treatment for HCC.

show abstract

High expression of MAGE-A9 contributes to stemness and malignancy of human hepatocellular carcinoma

Cited by 17 publications

References 43 publications

Recent Advances in Liver Cancer Stem Cells: Non-coding RNAs, Oncogenes and Oncoproteins

Recent Advances in Liver Cancer Stem Cells: Non-coding RNAs, Oncogenes and Oncoproteins

A comprehensive analysis of the MAGE family as prognostic and diagnostic markers for hepatocellular carcinoma

A Comprehensive Analysis of the MAGE Family as Prognostic and Diagnostic Markers for Hepatocellular Carcinoma

Contact Info

Product

Resources

About